All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

MK-677 for muscle gains: what the evidence actually says

More Gains tn

TikTok creator

31.1K viewsWatch on TikTok→

Quick answer

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that increases endogenous growth hormone and IGF-1 secretion, with clinical trials primarily conducted in elderly and GH-deficient populations rather than healthy young adults seeking body composition changes. The video promotes its availability in Tunisia without addressing its unregulated status, absence of FDA or EMA approval, or documented side effects including insulin resistance and fluid retention. Any consideration of GH secretagogue therapy should involve baseline IGF-1 testing and physician oversight, not social media availability announcements.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @more_gains_tn actually say?

Honestly, the transcript here is nearly impossible to work with. The auto-captions picked up something like "I'm a big cop, possibly sitting on the track down, because of my pride" and "I'm a close to Fava" - none of which is coherent English. What we can establish from context is the actual message: MK-677 is "available now" in Tunisia. That's the claim being made, framed around a bodybuilding audience chasing gains. The hashtags do the heavy lifting: #mk677, #bodybuilding, #gains. So we're fact-checking availability and implied efficacy of MK-677, not anything the creator coherently stated out loud.

This matters because the video has 31,000 views. When a product availability claim reaches that many people, the implicit message travels with it: this stuff works, it's accessible, go get it. That's worth scrutinizing even without a clean transcript.

Does the science back up MK-677's popularity?

Partially, and with serious caveats most bodybuilding TikTok ignores. MK-677, also called ibutamoren, is a ghrelin receptor agonist that stimulates growth hormone secretion. It is not a peptide in the strict biochemical sense. It's a small-molecule oral compound. The research base is real but limited.

A randomized controlled trial by Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) found that two years of MK-677 administration increased GH and IGF-1 levels in older adults but did not improve functional outcomes meaningfully. Earlier work by Chapman et al. (1996, Journal of Clinical Endocrinology and Metabolism) confirmed the GH-stimulating effect in healthy older adults. These are legitimate findings. But the populations studied were older adults with GH deficiency, not healthy young men trying to add muscle mass on a TikTok budget.

The side effect profile is also glossed over in bodybuilding communities: water retention, increased appetite, potential insulin resistance with prolonged use, and elevated cortisol. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) documented significant fluid retention and mild increases in fasting glucose in subjects using MK-677 long-term.

What did they get wrong, or right?

There's nothing specifically wrong in what was said, because what was said was incoherent. But the framing deserves pushback. Announcing availability of a research compound to a bodybuilding audience, with zero safety context, is irresponsible regardless of what country you're in.

MK-677 is not approved by the FDA. It is not approved by the EMA. In many jurisdictions it sits in a regulatory gray zone, sold as a "research chemical." Promoting it as something you can simply go get, with gain-focused hashtags, strips away the context that matters: unknown long-term safety in healthy young adults, no standardized dosing validated in clinical literature, and the very real possibility that products sold informally contain incorrect concentrations or outright substitutes.

To give credit where it's due: MK-677 has more clinical research behind it than many compounds promoted on bodybuilding TikTok. It's not snake oil. But "has some research" and "safe to buy from an unregulated source based on a TikTok" are very different claims.

What should you actually know about MK-677?

If you're curious about MK-677 or GH secretagogues broadly, the research is accessible and worth reading yourself rather than taking cues from a hype video. Here's what the literature actually supports.

  • MK-677 does increase GH pulse amplitude and IGF-1 levels. That is established (Copinschi et al., 1997, Sleep).
  • Effects on lean body mass in healthy adults are modest and studied over short periods, not the dramatic transformation bodybuilding culture implies.
  • Long-term safety data in young, healthy populations essentially does not exist. The studies were done in elderly or GH-deficient subjects.
  • Insulin sensitivity is a legitimate concern. Anyone with prediabetes or metabolic risk factors should not be experimenting with this compound casually.
  • Regulatory status varies by country. In Tunisia, as in many markets, enforcement of research chemical sales is inconsistent. That inconsistency does not equal safety or legitimacy.

If growth hormone optimization is something you're considering for legitimate health reasons, that conversation belongs with a licensed clinician who can order baseline labs, assess your actual GH axis, and monitor for adverse effects over time. A TikTok availability announcement is not a starting point for that conversation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For MK-677 for muscle gains: what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

MK-677 for muscle gains: what the evidence actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that increases endogenous growth hormone and IGF-1 secretion, with clinical trials primarily conducted in elderly and GH-deficient populations rather than healthy young adults seeking body composition changes.

FormBlends verdict

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that increases endogenous growth hormone and IGF-1 secretion, with clinical trials primarily conducted in elderly and GH-deficient populations rather than healthy young adults seeking body composition changes. The video promotes its availability in Tunisia without addressing its unregulated status, absence of FDA or EMA approval, or documented side effects including insulin resistance and fluid retention. Any consideration of GH secretagogue therapy should involve baseline IGF-1 testing and physician oversight, not social media availability announcements.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that increases endogenous growth hormone and IGF-1 secretion, with clinical trials primarily conducted in elderly and GH-deficient populations rather than healthy young adults seeking body composition changes. The video promotes its availability in Tunisia without addressing its unregulated status, absence of FDA or EMA approval, or documented side effects including insulin resistance and fluid retention. Any consideration of GH secretagogue therapy should involve baseline IGF-1 testing and physician oversight, not social media availability announcements.
  • MK-677 is not a peptide. It is a small-molecule oral ghrelin receptor agonist. Lumping it with peptides like BPC-157 or ipamorelin is a category error common in bodybuilding communities.
  • 2 clinical trials (Chapman et al. 1996, Nass et al. 2008, both in JCEM) confirm GH and IGF-1 elevation with MK-677, but neither was conducted in healthy young adults seeking muscle hypertrophy.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • MK-677 is not a peptide. It is a small-molecule oral ghrelin receptor agonist. Lumping it with peptides like BPC-157 or ipamorelin is a category error common in bodybuilding communities.
  • 2 clinical trials (Chapman et al. 1996, Nass et al. 2008, both in JCEM) confirm GH and IGF-1 elevation with MK-677, but neither was conducted in healthy young adults seeking muscle hypertrophy.
  • Documented side effects include water retention, increased appetite, elevated fasting glucose, and potential insulin resistance, none of which appear in the gains-focused TikTok framing.
  • MK-677 has no FDA approval, no EMA approval, and is classified as a research chemical in most jurisdictions. Availability in informal markets does not confer safety or legitimacy.
  • The transcript from this video was essentially incoherent in auto-caption form, which means 31,000 viewers are responding to hashtags and framing rather than any substantive information.
  • Long-term safety data for MK-677 in healthy adults under 50 does not exist in peer-reviewed literature. The clinical studies followed subjects for one to two years and used specific patient populations, not general fitness consumers.
  • If growth hormone support is a legitimate clinical goal, a physician can assess baseline IGF-1, cortisol, and fasting glucose before any intervention, providing context that a TikTok post cannot.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

More Gains tn · TikTok creator

31.1K views on this video

Available now in 🇹🇳✅ . . . . . #mk677 #bodybuilding #viralvideos #tunisia🇹🇳 #gains

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by More Gains tn, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.